Аннотация
Гипертрофическая кардиомиопатия (ГКМП) – важная нозология, которая наряду с двустворчатым аортальным клапаном является одним из двух наиболее распространенных моногенетических наследственных заболеваний сердца, характеризуется гетерогенностью клинической картины, анамнеза и ответа на терапию. ГКМП – это чаще диагноз исключения, то есть фенокопии, вторичные и специфические причины гипертрофии левого и правого желудочков необходимо исключить. В данной статье рассматривается проблема диагностики и дифференциальной диагностики ГКМП и ее синдромов в структуре полиорганной патологии на основе анализа литературных данных и результатов собственных исследований, так как проведение генетического тестирования с постановкой диагноза не всегда доступно. Приводятся критерии дифференциальной диагностики генетических форм гипертрофической кардиомиопатии и фенокопий. Цель настоящей работы – изучить современные подходы к диагностике ГКМП и ее дифференциальной диагностике с фенокопиями.
Литература
- Клинические рекомендации Министерства здравоохранения Российской Федерации. Гипертрофическая кардиомиопатия. М.; 2020.
- Elliott P.M., Anastasakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 2014; 35 (39): 2733–79. DOI: 10.1093/eurheartj/ehu284
- Ommen S.R., Mital S., Burke M.A., Day Sh. M., Deswal A., Elliott P. et al. AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2020; 25: 3022–55. DOI: 10.1016/j.jacc.2020.08.044
- Briasoulis A., Mallikethi-Reddy S., Palla M., Alesh I., Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: A meta-analysis. Heart. 2015; 101: 1406–11. DOI: 10.1136/heartjnl-2015-307682
- Marian A.J., Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 2017; 121 (7): 749–70. DOI: 10.1161/CIRCRESAHA.117.311059
- Coats C.J., Elliott P.M. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark. Med. 2013; 7 (4): 505–16. DOI: 10.2217/bmm.13.79
- Kelly M.A., Caleshu C., Morales A., Buchan J., Wolf Z., Harrison S.M. et al. Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: Recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel. Genet. Med. 2018; 20 (3): 351–9. DOI: 10.1038/gim.2017.218
- Wasfy M.M., Weiner R.B. Differentiating the athlete’s heart from hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 2015; 30: 500–5. DOI: 10.1097/HCO. 0000000000000203
- Maron M.S., Hauser T.H., Dubrow E., Horst T.A., Kissinger K.V., Udelson J.E., Manning W.J. Right ventricular involvement in hypertrophic cardiomyopathy. Am. J. Cardiol. 2007; 100 (8): 1293–8. DOI: 10.1016/j.amjcard. 2007.05.061
- Falcone D.M., Moore D., Lambert E.C. Idiopathic hypertrophic cardiomyopathy involving the right ventricle. Am. J. Cardiol. 1967; 19 (5): 735–40. DOI: 10.1016/0002-9149(67)90480-8 11. Bittencourt M.I., Cader S.A., Araújo D.V., Ferreira Salles A.L. Sudden death in hypertrophic cardiomyopathy. Int. J. Cardiovasc. Sci. 2016; 29 (6): 504–11. DOI: 10.5935/2359-4802.20160057
- Sweeting J., Ingles J., Timperio A., Patterson J., Ball K., Semsarian C. Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. Open Heart. 2016; 3 (2): e000484. DOI: 10.1136/openhrt-2016-000484
- Кактурский Л. Внезапная смерть (клиническая морфология). М.; 2000. Kaktursky L. Sudden death (clinical morphology). Moscow; 2000 (in Russ.).
- Hughes S.E. The pathology of hypertrophic cardiomyopathy. Histopathology. 2004; 44: 412–27. DOI: 10.1111/j.1365-2559.2004.01835.x
- Fananapazir L., Trary C.M., Leon M.B. et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989; 80 (5): 1259–68. DOI: 10.1161/01.cir. 80.5.1259
- Kelly B.S., Mattu A., Brady W.J. Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important considerations for the emergency physician. Am. J. Emerg. Med. 2007; 25 (1): 72–9. DOI: 10.1016/j.ajem.2006.04.017
- McLeod C.J., Ackerman M.J., Nishimura R.A., Tajik A.J., Gersh B.J., Ommen S.R. Outcome of patients with hypertrophic cardiomyopathy and a normal electro-cardiogram. J. Am. Coll. Cardiol. 2009; 54 (3): 229–33. DOI: 10.1016/j.jacc.2009.02.071
- Perosio A.M., Suarez L.D., Bunster A.M., Locreille А., Apkarian O.A., Vallazza M.A. et al. Pre-excitation syndrome and hypertrophic cardiomyopathy. J. Electrocardiol. 1983; 16 (1): 29–39. DOI: 10.1016/s0022-0736(83)80156-3
- Wilke I., Witzel K., Münch J., Pecha S., Blankenberg S., Reichenspurner H. et al. High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. J. Cardiovasc. Electrophysiol. 2016; 27 (7): 779–84. DOI: 10.1111/jce.12982
- Бокерия Л.А., Берсенёва М.И., Маленков Д.А. Аритмогенные осложнения гипертрофической кардиомиопатии. Анналы аритмологии. 2010; 7 (3): 62–9.
- Silbiger J.J. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights. J. Am. Soc. Echocardiogr. 2016; 29 (7): 622–39. DOI: 10.1016/j.echo. 2016.03.003
- Hendel R.C., Patel M.R., Kramer C.M., Poon M., Hendel R.C., Carr J.C. et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology. J. Am. Coll. Cardiol. 2006; 48: 1475–97. DOI: 10.1016/j.jacc.2006.07.003
- Nagueh S.F., Smiseth O.A., Appleton C.P., Byrd B.F. 3rd, Dokainish H., Edvardsen T. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An UPDATE from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016; 29 (4): 277–314. DOI: 10.1016/j.echo.2016.01.011
- Turvey L., Augustine D.X., Robinson S., Oxborough D., Stout M., Smith N. et al. Transthoracic echocardiography of hypertrophic cardiomyopathy in adults: a practical guideline from the British Society of Echocardiography. Echo Res. Pract. 2021; 8 (1): G61–G86. https://erp.bioscientifica.com/view/journals/echo/8/1/ERP-20- 042.xml (дата доступа 13.03.2021)
- Minami Y., Kajimoto K., Terajima Y., Yashiro B., Okayama D., Haruki S. et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2011; 57 (23): 2346–55. DOI: 10.1016/j.jacc.2011.02.033
- Noureldin R.A., Liu S., Nacif M.S., Judge D.P., Halushka M.K., Abraham T.P. et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2012; 14: 17. DOI: 10.1186/1532-429X-14-17
- Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S. et al. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. J. Am. Coll. Cardiol. 2011; 58 (25): e212–6. DOI: 10.1016/j.jacc.2011.06.011
- Harrigan C.J., Peters D.C., Gibson C.M., Maron B.J., Manning W.J., Maron M.S. et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011; 258 (1): 128–33. DOI: 10.1148/radiol.10090526 29. Rubinshtein R., Glockner J.F., Ommen S.R., Araoz P.A., Ackerman M.J., Sorajja P. et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ. Heart Fail. 2010; 3 (1): 51–8. DOI: 10.1161/CIRCHEARTFAILURE.109.854026
- Chan R.H., Maron B.J., Olivotto I., Pencina M.J., Assenza G.E., Haas T. et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014; 130 (6): 484–95. DOI: 10.1161/CIRCULATIONAHA.113.007094 642
- Nagueh S.F., Bierig S.M., Budoff M.J., Desai M., Dilsizian V., Eidem B. et al.; American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J. Am. Soc. Echocardiogr. 2011; 24 (5): 473–98. DOI: 10.1016/j.jacc.2011.06.011
- Scott P.A., Rosengarten J.A., Curzen N.P., Morgan J.M. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. Eur. J. Heart Fail. 2013; 15 (9): 1019–27. DOI: 10.1093/eurjhf/hft053
- Mewton N. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011; 57 (8): 891–903. DOI: 10.1016/j.jacc.2010.11.013
- Ringenberg J., Deo M., Filgueiras-Rama D., Pizarro G., Ibañ ez B., Peinado R. et al. Effects of fibrosis morphology on reenterat ventricular tachycardia inducibility and simulation fidelity in patient-derived models. Clin. Med. Insights Cardiol. 2014; 8: 1–13. DOI: 10.4137/CMC. S15712
- Kuruvilla S., Adenaw N., Katwal A.B., Lipinski M.J., Kramer C.M., Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ. Cardiovasc. Imaging. 2014; 7 (2): 250–8. DOI: 10.1161/CIRCIMAGING.113.001144
- Méndez C., Soler R., Rodríguez E., Barriales R., Ochoa J.P., Monserrat L. Differential diagnosis of thickened myocardium: an illustrative MRI review. Insights Imaging. 2018; 9: 695–707. DOI: 10.1007/s13244-018-0655-9
- Maron B.J., Haas T.S., Ahluwalia A., Murphy C.J., Garberich R.F. Demographics and epidemiology of sudden deaths in young competitive athletes: From the United States National Registry. Am. J. Med. 2016; 129 (11): 1170–7. DOI: 10.1016/j.amjmed.2016.02.031
- Papadopoulou-Legbelou K., Gogou M., Evangeliou A. Cardiac manifestations in children with inborn errors of metabolism. Indian Pediatr. 2017; 54: 667–73. DOI: 10.1007/s13312-017-1131-1
- Meyers D.E., Basha H.I., Koenig M.K. Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management. Tex. Heart Inst. J. 2013; 40: 385–94.
- Tariq M., Ware S. Importance of genetic evaluation and testing in pediatric cardiomyopathy. World J. Cardiol. 2014; 6: 11: 1156–65. DOI: 10.4330/wjc.v6.i11.1156 41. Wanner C., Arad M., Baron R., Burlina A., Elliott P.M., Feldt-Rasmussen U. et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol. Genet. Metab. 2018; 124 (3): 189–203. DOI: 10.1016/j.ymgme.2018.06.004
- Nakagama Y., Inuzuka R., Ichimura K., Hinata M., Takehara H., Takeda N. et al. Accelerated cardiomyocyte proliferation in the heart of a neonate with LEOPARD syndrome-associated fatal cardiomyopathy. Circ. Heart Fail. 2018; 11 (4): e004660. DOI: 10.1161/CIRCHEARTFAILURE.117.004660
Об авторах
- Берсенева Марина Ивановна, канд. мед. наук, заведующая отделением хирургического лечения кардиомиопатий; ORCID
- Хугаева Алина Ахсарбековна, канд. мед. наук, мл. науч. сотр., кардиолог; ORCID
- Бельский Василий Васильевич, мл. науч. сотр., кардиохирург; ORCID
- Бокерия Лео Антонович, академик РАН и РАМН, президент; ORCID
